Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Veure altres versions (1)

<p><strong>Background</strong> Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absenc...

Descripció completa

Dades bibliogràfiques
Autors principals: Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.
Format: Journal article
Idioma:English
Publicat: Elsevier 2020

Ítems similars